GENENTECH, INC for GENENTECH INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 14, 2014 | $836,600 | Replaced |
| 2nd Quarter - Amendment | Oct 15, 2014 | $1,071,595 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies, 340(b) Drug Discount Program, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare presciption drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and biologics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis. S. 959 - Pharmaceutical Quality, Security, and Accountability Act- legislation regarding pharmacy compounding and track and trace proposals. Public Law 113-67, Continuing Appropriations Resolution for 2014 - General public health spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant director |
| ANNA GRIFFIN New | Sr. Director |
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations, Tax reform, 340 B pricing, research and development tax credit, pandemic preparedness, federal appropriations., Issues related to comprehensive tax reformed the tax treatment of foreign-owned U.S. corporations. S__, Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act (tax extenders), including the R&D tax credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant director |
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues - (all provisions), Cyber security, Transpacific partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant director |
Health Issues HCR
Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant director |
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | Vice President |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant director |
| ANNA GRIFFIN New | Sr. Director |
| EVAN MORRIS | Vice President |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
BUD: FY15 Labor, HHS and Education Appropriations related to preparedness for pandemic influenza, HIV/AIDS, hepatitis screening, care and treatment, and access to breast cancer treatment, Issues related to FDA & HHS program funding, FY15 Labor Health and Human Services, and Education, and Related Agencies, H.R. 4800, and FY 15 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills, Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant director |
| EVAN MORRIS | Vice President |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.